All In Biotech

Drug Trial Radar · NCT07004049

Optimising TREATment for Severe Gram-Negative Bacterial Infections

TREAT-GNB [CR-GNB]

Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Apr 21, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
National University of SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The University of Queensland; European Clinical Research Alliance for Infectious Diseases (ECRAID)
First posted
Jun 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria. In the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.

Conditions

  • Bloodstream Infection
  • Ventilator Associated Bacterial Pneumonia
  • Hospital Acquired Bacterial Pneumonia
  • Carbapenem Resistant Bacterial Infection
  • Multidrug Resistance

Interventions

  • Colistin/Polymyxin B + SulbactamDrug

    For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand and Singapore

  • Colistin/Polymyxin B + Tigecycline/EravacyclineDrug

    For carbapenem-resistant Acintobacter, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand and Singapore

  • Colistin/Polymyxin B + MeropenemDrug

    For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia and Singapore

  • Ceftazidime-avibactam + SulbactamDrug

    For carbapenem-resistant Acinetobacter infections in China, Malaysia, Thailand, Singapore and Australia.

  • Ceftazidime-avibactam + FosfomycinDrug

    For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Malaysia, Thailand and Singapore

  • Ceftazidime-avibactamDrug

    For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.

  • Ceftazidime-avibactam + AztreonamDrug

    For carbapenem-resistant Enterobacterales infections in China, Malaysia, Thailand, Singapore, Europe and Australia.

  • Ceftazidime-avibactam + Colistin/Polymyxin BDrug

    For carbapenem-resistant Pseudomonas aeruginosa in China, Malaysia, Thailand, Singapore and Europe.

  • High-dose meropenemDrug

    For carbapenem-resistant Enterobacterales infection in Europe

  • Meropenem + FosfomycinDrug

    For carbapenem-resistant Enterobacterales in Europe

  • Meropenem-vaborbactamDrug

    For carbapenem-resistant Enterobacterales infection in Europe

  • CefiderocolDrug

    For carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacterales infections in Europe and Australia.

  • Ceftolozane-tazobactamDrug

    For carbapenem-resistant Pseudomonas aeruginosa in Europe and Australia.

  • Ceftolozane-tazobactam + MeropenemDrug

    For carbapenem-resistant Pseudomonas aeruginosa in Europe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical outcomeTime frame: 28 days post-randomisation

Locations

41 sites in 12 countries. Site status is shown where the registry gives one.

  • Princess Alexandra Hospital

    Brisbane, Australia · Not yet recruiting

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, Australia · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China · Not yet recruiting

  • The Second Affiliated Hospital, Xi'an Jiang Tong University

    Xi'an, China · Not yet recruiting

  • Xuzhou First People's Hospital

    Xuzhou, China · Not yet recruiting

  • American University of Beirut Medical Center

    Beirut, Lebanon · Not yet recruiting

  • Queen Elizabeth I

    Kota Kinabalu, Sabah, Malaysia · Not yet recruiting

  • Queen Elizabeth II

    Kota Kinabalu, Sabah, Malaysia · Not yet recruiting

  • Miri Sarawak Hospital

    Miri, Sarawak, Malaysia · Not yet recruiting

  • Ampang Hospital

    Ampang, Selangor, Malaysia · Not yet recruiting

  • Hospital Sungai Buloh

    Sungai Buloh, Selangor, Malaysia · Not yet recruiting

  • Hamad Medical Corporation

    Doha, Qatar · Not yet recruiting

  • King Saud bin Abdulaziz University for Health Sciences

    Riyadh, Saudi Arabia · Not yet recruiting

  • National University Hospital

    Singapore, Singapore, Singapore · Recruiting

  • Helen Joseph Hospital

    Johannesburg, South Africa · Not yet recruiting

  • Hospital General Universitario Dr. Balmis

    Alicante, Spain · Not yet recruiting

  • Hospital Universitario de Badajoz

    Badajoz, Spain · Not yet recruiting

  • Hospital Universitario de Cruces

    Barakaldo, Spain · Not yet recruiting

  • Hospital del Mar Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario Bellvitge

    Barcelona, Spain · Not yet recruiting

  • Hospital Universitario Reina Sofía Córdoba

    Córdoba, Spain · Not yet recruiting

  • Hospital Universitario San Cecilio

    Granada, Spain · Not yet recruiting

  • Hospital Universitario Virgen de las Nieves

    Granada, Spain · Not yet recruiting

  • Hospital Clínico San Carlos

    Madrid, Spain · Not yet recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario de La Princesa

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Not yet recruiting

  • Hospital Regional Universitario de Málaga

    Málaga, Spain · Not yet recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Not yet recruiting

  • Hospital Álvaro Cunqueiro

    Pontevedra, Spain · Not yet recruiting

  • Hospital Universitario de Donostia

    San Sebastián, Spain · Not yet recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Spain · Not yet recruiting

  • Hospital Universitario Virgen Macarena

    Seville, Spain · Not yet recruiting

  • Hospital Universitario Virgen de Valme

    Seville, Spain · Not yet recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Spain · Not yet recruiting

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Spain · Not yet recruiting

  • Phramongkutkloa Hospital

    Bangkok, Thailand · Not yet recruiting

  • Rajavithi Hospital

    Bangkok, Thailand · Not yet recruiting

  • Maharaj Nakorn Chiang Mai Hospital, Chiangmai University

    Chiang Mai, Thailand · Not yet recruiting

  • İstanbul Medipol Üniversitesi

    Istanbul, Turkey (Türkiye) · Not yet recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.